Clinical Trial Update: A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia [Phase 3]

View source ↗

Summary

A two-part Phase 3 clinical trial evaluating WS016 for hyperkalemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperkalemia

Drugs mentioned

• WS016

Snippet

Sponsor: Waterstone Pharmaceutical (Wuhan) Co., LTD. | Conditions: Hyperkalemia | Phase 3 | Status: RECRUITING